Alnylam Pharmaceuticals (ALNY) - Net earnings per share (EPS TTM)

By leveraging a closed RNA interference ecosystem, Alnylam Pharmaceuticals (ALNY) creates high switching costs for alternative treatments. The TTM net income per share trend reflects balanced demand during periods of market volatility, with 19.84 representing the current level of this metric. This stability is further supported by a workforce of leading geneticists and streamlined international distribution channels for innovative drugs.
Comprehensive metric breakdowns and analytics for Alnylam Inc. (ALNY)

Identifying fundamentally resilient assets requires an analysis of real returns, measured by the trailing 12-month earnings per share (EPS), which divides the company's bottom line by the total number of outstanding shares. For Alnylam Pharmaceuticals (ALNY), which possesses significant pricing power in the RNA interference segment, the trend of this metric confirms the quality of earnings and the predictability of cash flows, allowing the trailing 12-month earnings per share to distinguish objective growth from market speculation.